Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease - Trial NCT06299631
Access comprehensive clinical trial information for NCT06299631 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Montpellier and is currently Completed. The study focuses on Crohn's Disease. Target enrollment is 133 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital, Montpellier
Timeline & Enrollment
N/A
Jan 01, 2015
Dec 01, 2023
Primary Outcome
Endoscopic recurrence rate
Summary
Aim of the study:
 
 To evaluate risk factors of endoscopic relapse after ileocolic resection in a cohort of
 Crohn's disease patients treated with anti-TNF agents.
 
 Methods:
 
 From 2014 to 2022, all consecutive patients who underwent ileocolic resection for Crohn's
 disease treated with anti-TNF agents in two referral tertiary center were prospectively
 collected.
 
 Considering exclusion criteria, data from 114 patients were analyzed. The cohort was
 separated into 2 groups according to study period.
 
 Short and long-term outcomes were compared between the two groups.
 
 Primary outcome:
 
 Endoscopic recurrence (defined as i2 lesions according to Rutgeerts classification) 6
 months after surgery
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06299631
Non-Device Trial